Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women

Br J Obstet Gynaecol. 1990 Oct;97(10):939-44. doi: 10.1111/j.1471-0528.1990.tb02451.x.

Abstract

To identify changes in haemostatic balance during continuous oestradiol-progestogen treatment, 60 postmenopausal women with climacteric complaints, mean age 55.4 years (range 44-68) were randomly allocated to receive one of four hormone replacement regimens for one year. All four formulations were administered daily and continuously, each contained 2 mg of 17 beta-oestradiol in combination with either norethisterone acetate, 1 mg (group A) or 0.5 mg (group B) or megestrol acetate, 5 mg (group C) or 2.5 mg (group D). No significant changes occurred during treatment within or between the groups in platelet count, fibrinogen and 2-antiplasmin. Activated partial thromboplastin time was shortened (P less than 0.05) in group D and a decline in factor VII activity and antigen (P less than 0.001) and in ATIII activity (P less than 0.05) was noted in group A. Protein C tended to decline in all treatment groups but statistically significant changes were noted only in groups A and C. Two women developed crural thrombosis during the observation period.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antithrombin III / analysis
  • Climacteric / drug effects
  • Double-Blind Method
  • Estradiol / therapeutic use*
  • Estrogen Replacement Therapy / adverse effects
  • Estrogen Replacement Therapy / methods*
  • Factor VII / analysis
  • Female
  • Hemostasis / drug effects*
  • Humans
  • Menopause / blood*
  • Middle Aged
  • Partial Thromboplastin Time
  • Plasminogen / analysis
  • Plasminogen Inactivators / analysis
  • Protein C / analysis
  • Thrombosis / etiology
  • von Willebrand Factor / analysis

Substances

  • Plasminogen Inactivators
  • Protein C
  • von Willebrand Factor
  • Estradiol
  • Antithrombin III
  • Factor VII
  • Plasminogen